Updates are available Correction dated 2020-10-21

Article History

Received: 7 August 2020

Accepted: 27 August 2020

First Online: 2 September 2020

Change Date: 21 October 2020

Change Type: Correction

Change Details: The original version of this article unfortunately contained a mistake in Fig. 2 caption.

Compliance with ethical standards

:

: Olivier Rascol has acted as a scientific advisor for drug companies developing antiparkinsonian medications (Abbott, Abbvie, Acorda, Adamas, BIAL, Biogen, Boehringer-Ingelheim, Cynapsus, GSK, Impax, Merck, Osmotica, Merz pharmaceuticals, Oxford-Biomedica, Lundbeck, Novartis, Prexton, Servier, Sunovion, TEVA, UCB, Zambon) and has received unrestricted scientific grants from academic non-profit entities (Toulouse University Hospital, French Health Ministry, MJFox Foundation, France-Parkinson, European Commission). Laurence Negre-Pages reports grants from the Association France-Parkinson, ADREN, Boehringer Ingelheim, Eisai, Faust Pharmaceuticals, GlaxoSmithKline, Pierre Fabre Médicaments, Solvay Pharma, Wyeth Lederlé for funding this project and that she owns stock options from LN PHARMA, which was one of the sponsors of this study. Philippe Damier has received honoraria for conferences from Teva and Novartis. Wassilios Meissner has received fees for editorial activities from Springer Nature and Elsevier, for consultancy activities from Biohaven and Lundbeck, and teaching honoraria from UCB and Boehringer Ingelheim. Santiago Perez-Lloret received honoraria from Osmotica and Merz pharmaceuticals. Arnaud Delval, Pascal Derkinderen, Alain Destée, Margherita Fabbri, Amine Rachdi, and Francois Tison have no conflict of interest to declare.

: Include appropriate approvals or waivers.

: The study was approved by Institutional Review Boards at the participating centers, and French regulatory authorities. It was undertaken following international guidelines. Signed informed consent was obtained from all patients.

: All authors approved the publication of this article.